skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiation dose estimates for C-11 iomazenil, a benzodiazepine receptor radioligand

Journal Article · · Journal of Nuclear Medicine
OSTI ID:198018
; ;  [1]
  1. Oak Ridge Institute for Science and Education, TN (United States); and others

SPECT imaging of the brain with I-123 iomazenil has shown avid uptake of the radioligand in a distribution consistent with benzodiazepine receptor binding. It was desirable to radiolabel this compound with a positron emitting radionuclide so that quantitation of the receptor density could be assessed with PET imaging. Radiation dose estimates for C-11 iomazenil were calculated prior to obtaining Institutional Review Board approval of this procedure. A previously published multicompartmental model was used as the biological model for estimating residence times associated with the C-11 labeled iomazenil. According to this model, 85-90% is excreted in the urine and 10-15% in the feces. A dynamic, voiding urinary bladder model was utilized for activity excreted renally and the ICRP 30 gastrointestinal tract kinetic model was used for activity excreted via the hepatobiliary system. Absorbed doses from C-11 (I-123) iomazenil to the urinary bladder were calculated to be 0.099 mGy/MBq (0.19 mGy/MBq) for a 4.8 hour bladder voiding interval. Shortening the bladder voiding interval to 2.0 hours had little effect on the bladder wall dose (0.095 mGy/MBq). However, a 30-minute void interval was estimated to lower the bladder wall dose substantially (0.045 mGy/MBq). Absorbed dose to the kidney was higher for C-11 iomazenil (0.054 vs 0.031 mGy/MBq) than for I-123 iomazenil due to rapid, early renal excretion of this very short-lived positron emitter. Doses to the gastrointestinal tract were estimated to be 4- to 20-fold lower for C-11 iomazenil compared to I-123 iomazenil. Overall, labeling iomazenil with C-11 rather than I-123 greatly reduces the radiation dose, per unit administered, to all organs except the kidneys.

OSTI ID:
198018
Report Number(s):
CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0159
Journal Information:
Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
Country of Publication:
United States
Language:
English